1 research outputs found
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma
Further optimization
of an initial DP<sub>2</sub> receptor antagonist
clinical candidate NVP-QAV680 led to the discovery of a follow-up
molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)acetic acid
(compound <b>11</b>, NVP-QAW039, fevipiprant), which exhibits
improved potency on human eosinophils and Th2 cells, together with
a longer receptor residence time, and is currently in clinical trials
for severe asthma